Clinical and Biochemical Determinants of the Systemic Inflammation Response Index During Vancomycin Therapy
Die Pharmazie · 29.06.2026 · 81 (6)
DOI: 10.31083/pharmazie51565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Die Pharmazie, online erschienen am 29.06.2026. Verfasst von Mohammad A Alfhili und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, 12372 Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Vancomycin, Anti-Bacterial Agents, Inflammation, Systemic Inflammatory Response Syndrome. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ongoing Research Funding Program, King Saud University, Riyadh, Saudi Arabia.
Abstract (Originalsprache)
Background:Vancomycin (VAN) is the standard of care for Gram-positive infections. The systemic inflammation response index (SIRI) has been associated with infections and sepsis across various clinical settings; however, the correlates and determinants of the SIRI during VAN therapy remain unexplored. This retrospective cross-sectional study aimed to identify the determinants of the SIRI among adults treated with VAN.Methods:Medical records of 299 patients who received VAN were analyzed consecutively. Prevalence rates were calculated; Spearman’s correlation and regression models were employed to evaluate associations; risk assessment was conducted using prevalence ratios and odds ratios; diagnostic potential was assessed using receiver operating characteristic curves.Results:The SIRI was significantly higher in intensive care unit (ICU) patients than in non-ICU patients receiving VAN therapy (p < 0.0001). Age, blood pressure, creatinine, Na+, CO2, albumin, aspartate transaminase (AST), gamma-glutamyl transferase (GGT), bilirubin, coefficient of variation in red cell distribution width (RDW-CV), and platelet count were significantly and differentially correlated with the SIRI. In the adjusted analysis, ICU requirement emerged as the strongest independent predictor of SIRI, with ICU patients showing a 2.13-fold higher SIRI(p < 0.0001). Moreover, the prevalence of ICU requirement was 1.61 times higher in individuals with increased SIRI (p = 0.0018), whose odds of ICU requirement were 2.16 times higher (p = 0.0016). The SIRI also demonstrated moderate discriminatory ability, with the highest performance observed in patients younger than 50 years (area under the curve [AUC] = 0.731, p = 0.0001).Conclusions:The SIRI is a novel and cost-effective marker that is correlated with distinct demographic and clinical variables and independently associated with ICU requirement in VAN-treated patients and may aid in the risk stratification and management of this vulnerable patient cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, 12372 Riyadh, Saudi Arabia.
Förderung
- Ongoing Research Funding Program, King Saud University, Riyadh, Saudi Arabia
Zitieren
APA
Alfhili, M. A., Alazmi, S. A., & Alsughayyir, J. (2026). Clinical and Biochemical Determinants of the Systemic Inflammation Response Index During Vancomycin Therapy. Die Pharmazie, 81(6). https://doi.org/10.31083/pharmazie51565
Vancouver
Alfhili MA, Alazmi SA, Alsughayyir J. Clinical and Biochemical Determinants of the Systemic Inflammation Response Index During Vancomycin Therapy. Die Pharmazie. 2026;81(6). doi:10.31083/pharmazie51565
BibTeX
@article{Alfhili2026,
author = {Alfhili, Mohammad A and Alazmi, Sahar A and Alsughayyir, Jawaher},
title = {Clinical and Biochemical Determinants of the Systemic Inflammation Response Index During Vancomycin Therapy},
journal = {Die Pharmazie},
year = {2026},
volume = {81},
number = {6},
doi = {10.31083/pharmazie51565}
}
EUVIMED